1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd.

OTSKF
Otsuka Holdings Co., Ltd.US flagOther OTC
64.57
USD
- -
- -
34.00BMarket Cap
Otsuka Holdings Co., Ltd.
OTSKF
(Other OTC)

Recent

price

64.57

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,252.48
2,069.75
2,208.06
2,675.48
- -
2,634.32
2,206.42
2,288.37
2,384.4
2,575.59
2,623.61
2,762.43
3,203.35
3,719.59
4,303.37
4,657.41
4,016.77
Revenue per Share
164.54
165.24
221.94
278.07
- -
188.17
170.83
207.61
152.24
234.55
273.16
231.32
246.81
224.1
633.76
685.06
233.67
Basic EPS, GAAP
104.55
200.03
108.56
288.25
- -
336.54
129.96
46.68
114.82
238.33
248.87
213.34
191.8
310.6
416.1
494.08
306.89
Free Cash Flow per Basic Share
11.9
48
53.17
60.32
- -
90.77
100.95
101.25
102.05
102.49
102.7
103.22
102.41
102.55
123.31
133.89
112.89
Dividend per Share
1,381.66
1,210.78
1,392.78
1,642.05
- -
2,290.77
2,382.27
2,487.94
2,419.59
2,557.18
2,737.03
2,883.39
3,013.07
3,137.92
3,668.42
4,315.1
3,278.34
Book Value per Share
2,169.88
2,071.67
2,268.19
2,428.22
- -
1,848.18
1,955.58
2,060.77
1,778.17
1,922.39
2,145.11
2,261.88
2,482.95
2,886.19
3,295.97
3,802.39
3,344.04
Tangible Book Value per Share
501
558
552
543
- -
542
542
542
542
542
542
542
543
543
541
530
543
Basic Weighted Avg Shares
1,127,589
1,154,573
1,218,055
1,452,759
- -
1,427,375
1,195,547
1,239,952
1,291,981
1,396,240
1,422,826
1,498,276
1,737,998
2,018,568
2,329,861
2,468,892
2,179,960
Sales/Revenue/Turnover
25.52
12.88
13.93
13.68
- -
9.56
7.12
6.84
9.79
12.49
14.87
10.18
10.71
14.45
17.85
19.12
16.22
Operating Margin (%)
45,600
45,596
42,998
47,098
- -
59,156
59,574
62,235
59,275
75,690
79,423
84,855
93,761
97,777
107,979
116,167
105,089
Depreciation Expense
82,369
92,174
122,429
150,989
- -
101,957
92,563
112,492
82,492
127,151
148,137
125,463
133,906
121,616
343,120
363,150
126,816
Net Income, GAAP
31.73
34.82
30.4
27.43
- -
33.88
20.01
- -
22.01
24.39
20.13
21.04
20.63
12.03
- -
21.75
10.24
Effective Tax Rate (%)
7.3
7.98
10.05
10.39
- -
7.14
7.74
9.07
6.38
9.11
10.41
8.37
7.7
6.02
14.73
14.71
5.82
Profit Margin (%)
645,671
700,940
734,170
731,421
753,798
660,544
677,242
624,477
505,600
547,460
587,514
581,479
652,837
659,564
734,308
872,894
775,414
Working Capital
35,825
31,733
12,111
19,973
22,660
234,292
193,972
176,961
146,132
188,487
181,878
162,480
150,004
125,915
160,887
166,919
129,383
LT Debt
1,163,325
1,222,764
1,325,071
1,510,759
1,685,662
1,727,369
1,738,441
1,821,949
1,732,265
1,795,439
1,883,432
2,045,189
2,262,369
2,436,317
2,778,164
3,099,761
2,666,772
Total Equity
16.45
7.45
8.57
9.42
- -
4.68
3.33
- -
4.9
6.55
8.05
5.48
6.21
9.89
- -
11.61
11.2
Return on Invested Capital (%)
10.76
11.88
15.2
16.32
- -
7.57
6.44
- -
5.41
8
9.05
7.07
7.36
6.45
- -
15.88
6.5
Return on Capital (%)
13.01
13.48
16.96
18.19
- -
8.4
7.31
8.53
6.2
9.43
10.32
8.23
8.37
7.29
18.6
17
7.27
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
88,272
71,975
118,583
LT Borrowings
69,200
68,673
67,900
LT Finance Leases
56,715
58,818
61,483
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
543
543
543
Market Capitalization
2,997,774
3,152,625
3,449,188

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,326,797
1,305,155
1,499,238
Cash, Cash Equivalents & STI
529,403
476,306
591,052
Accounts Receivable, Net
474,086
469,636
530,612
Inventories
249,581
273,827
296,778
Total Current Liabilities
667,233
631,469
723,824
Payables & Accruals
- -
- -
- -
ST Debt
88,272
71,975
118,583
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.16%
10.5%
11.58%
Free Cash Flow
22.02%
17.51%
16.26%
Net Income, GAAP
22.65%
34.04%
5.84%
Sales/Revenue/Turnover
6.05%
11.77%
5.97%
Total Cash Common Dividend
3.92%
5.24%
6.31%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
519,517
589,412
- -
- -
2,329,861
2025
- -
- -
- -
- -
2,468,892
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
142.59
56.04
- -
- -
633.76
2025
- -
- -
- -
- -
685.06
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
60.64
2.14
- -
- -
123.31
2025
- -
- -
- -
- -
133.89
2026
- -
- -
- -
- -
- -
Similar Companies
Kyowa Kirin Co., Ltd. (KYKOF)
Ono Pharmaceutical Co., Ltd. (OPHLF)
Scilex Holding Company (SCLXW)
Novartis AG (NVS)
Santen Pharmaceutical Co., Ltd. (4536.T)
Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
Business
Otsuka Holdings Co., Ltd. operates as a holding company overseeing a global group engaged in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops and markets pharmaceutical products in psychiatry, neurology, oncology, cardiovascular and renal systems, digestive systems, ophthalmology, diagnostics, intravenous solutions, and medical devices; nutraceuticals and consumer products including Pocari Sweat ion supply drink, Calorie Mate nutritional food, Equelle women's health supplements, Body-mainte conditioning foods and beverages, and OS-1 oral rehydration solution; and other offerings such as soft drinks, wines, functional foods, clinical testing equipment, cosmetics, chemical products including hydrazine and potassium titanate, IT solutions, bio-pesticides, infusion and clinical nutrition products, stable isotopes, and polyolefin foams. Founded in 1921 with the holding company established in 2008, Otsuka Holdings is headquartered in Tokyo, Japan, with principal operations in Japan, the United States, Europe, and Asia. Recent developments include the acquisition of Jnana Therapeutics Inc. in 2024 to bolster its pipeline in phenylketonuria and autoimmune diseases through Otsuka America Inc., the formation of a joint venture with ICU Medical Inc. in late 2024 for North American IV solutions manufacturing effective early 2025 under Otsuka Pharmaceutical Factory, and the submission of a new drug application to the U.S. FDA in November 2025 for centanafadine to treat ADHD in children.

Company News

APIChat

  • seekingalpha.com

    Aristotle International Equity ADR WM Q1 2026 Contributors And Detractors

  • seekingalpha.com

    Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript

  • seekingalpha.com

    Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript

  • defenseworld.net

    Otsuka (OTCMKTS:OTSKF) Trading Up 3% – Should You Buy?

  • reuters.com

    US FDA approves Otsuka's kidney disease drug

  • seekingalpha.com

    Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript